Skip to main content

Table 2 Echocardiographic assessment of In Vivo residual LV function at 4 weeks post-MI

From: Type 1 diabetes mellitus abrogates compensatory augmentation of myocardial neuregulin-1β/ErbB in response to myocardial infarction resulting in worsening heart failure

Parameter

CV

DM

Sham MI

MI

DM + MI

LVFS,%

43.4 ± 1.9

34.3 ± 1.1*

40.4 ± 1.0

25.2 ± 2.2†#

17.9 ± 0.7*†#‡

LVEF,%

73.3 ± 2.3

61.5 ± 1.5*

69.5 ± 1.2

47.5 ± 3.5†#

35.5 ± 1.4*†#‡

LVIDd, mm

6.3 ± 0.22

7.7 ± 0.20*

6.6 ± 0.24

9.3 ± 0.55†#

9.2 ± 0.67*†

LVIDs, mm

3.6 ± 0.23

5.1 ± 0.17*

4.2 ± 0.19

7.0 ± 0.55†#

7.8 ± 0.37*†#

Heart Rate, bpm

350 ± 23.5

241 ± 9.0*

376 ± 16.5

361 ± 11.1#

299 ± 9.3†#‡

  1. LVFS, left ventricular fractional shortening; LVEF, left ventricular ejection fraction; LVIDd, left ventricular internal dimension, diastolic; LVIDs, left ventricular internal dimension, systolic. Values are mean ± standard error of the mean of four to six animals. *P < 0.05 vs. CV; P < 0.05 vs. Sham MI; #P < 0.05 vs. DM; P < 0.05 vs. MI.